======= TRIP13 ======= == Gene Information == * **Official Symbol**: TRIP13 * **Official Name**: thyroid hormone receptor interactor 13 * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=9319|9319]] * **UniProt**: [[https://www.uniprot.org/uniprot/Q15645|Q15645]] * **Interactions**: [[https://thebiogrid.org/search.php?search=TRIP13&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20TRIP13|Open PubMed]] * **OMIM**: [[https://omim.org/entry/604507|Open OMIM]] == Function Summary == * **Entrez Summary**: N/A * **UniProt Summary**: Plays a key role in chromosome recombination and chromosome structure development during meiosis. Required at early steps in meiotic recombination that leads to non-crossovers pathways. Also needed for efficient completion of homologous synapsis by influencing crossover distribution along the chromosomes affecting both crossovers and non-crossovers pathways. Also required for development of higher-order chromosome structures and is needed for synaptonemal-complex formation. In males, required for efficient synapsis of the sex chromosomes and for sex body formation. Promotes early steps of the DNA double- strand breaks (DSBs) repair process upstream of the assembly of RAD51 complexes. Required for depletion of HORMAD1 and HORMAD2 from synapsed chromosomes (By similarity). Plays a role in mitotic spindle assembly checkpoint (SAC) activation (PubMed:28553959). {ECO:0000250|UniProtKB:Q3UA06, ECO:0000269|PubMed:28553959}. |AAA| |meiotic recombination checkpoint| |meiotic cell cycle checkpoint| |female meiosis I| |negative regulation of meiotic nuclear division| |male germ cell nucleus| |negative regulation of meiotic cell cycle| |oocyte maturation| |synaptonemal complex assembly| |spindle checkpoint| |mitotic spindle assembly checkpoint| |spindle assembly checkpoint| |mitotic spindle checkpoint| |synaptonemal complex organization| |negative regulation of mitotic metaphase/anaphase transition| |male meiosis I| |negative regulation of metaphase/anaphase transition of cell cycle| |negative regulation of mitotic sister chromatid separation| |negative regulation of chromosome separation| |negative regulation of mitotic sister chromatid segregation| |regulation of meiotic nuclear division| |female meiotic nuclear division| |negative regulation of sister chromatid segregation| |negative regulation of chromosome segregation| |oocyte development| |negative regulation of mitotic nuclear division| |oocyte differentiation| |synapsis| |male meiotic nuclear division| |negative regulation of nuclear division| |regulation of meiotic cell cycle| |reciprocal meiotic recombination| |regulation of mitotic metaphase/anaphase transition| |homologous recombination| |regulation of metaphase/anaphase transition of cell cycle| |negative regulation of reproductive process| |regulation of mitotic sister chromatid separation| |homologous chromosome segregation| |regulation of chromosome separation| |chromosome organization involved in meiotic cell cycle| |regulation of mitotic sister chromatid segregation| |oogenesis| |regulation of sister chromatid segregation| |transcription coregulator activity| |meiotic chromosome segregation| |regulation of chromosome segregation| |meiosis I| |meiosis I cell cycle process| |chromosome| |female gamete generation| |negative regulation of chromosome organization| |anatomical structure maturation| |spermatid development| |meiotic nuclear division| |mitotic cell cycle checkpoint| |spermatid differentiation| |cell maturation| |regulation of reproductive process| |meiotic cell cycle process| |regulation of mitotic nuclear division| |double-strand break repair| |regulation of nuclear division| |cell cycle checkpoint| |negative regulation of mitotic cell cycle phase transition| |nuclear chromosome segregation| |DNA recombination| |meiotic cell cycle| |negative regulation of cell cycle phase transition| |developmental maturation| |germ cell development| |chromosome segregation| |nuclear division| |negative regulation of mitotic cell cycle| |organelle fission| |negative regulation of cell cycle process| |regulation of chromosome organization| |cellular process involved in reproduction in multicellular organism| |negative regulation of organelle organization| |regulation of mitotic cell cycle phase transition| |regulation of cell cycle phase transition| |transcription by RNA polymerase II| |DNA repair| |spermatogenesis| |male gamete generation| |negative regulation of cell cycle| |mitotic cell cycle process| |regulation of mitotic cell cycle| |transcription, DNA-templated| |nucleic acid-templated transcription| |RNA biosynthetic process| |developmental process involved in reproduction| |mitotic cell cycle| |gamete generation| |negative regulation of cellular component organization| |DNA metabolic process| |regulation of cell cycle process| |cellular response to DNA damage stimulus| |multicellular organismal reproductive process| |sexual reproduction| |multicellular organism reproduction| |multi-organism reproductive process| |cell cycle process| |chromosome organization| |identical protein binding| |nucleobase-containing compound biosynthetic process| |heterocycle biosynthetic process| |aromatic compound biosynthetic process| |regulation of cell cycle| |regulation of organelle organization| |organic cyclic compound biosynthetic process| |cell cycle| |reproductive process| |reproduction| |ATP binding| |cellular nitrogen compound biosynthetic process| |cell development| |RNA metabolic process| |cellular response to stress| |cellular macromolecule biosynthetic process| |macromolecule biosynthetic process| |gene expression| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp187|proTAME 5μM R04 exp187]]|-4.23| |[[:results:exp217|Mdivi-1 15μM R05 exp217]]|-3.84| |[[:results:exp177|Apcin 25μM plus proTAME 2μM R04 exp177]]|-3.74| |[[:results:exp46|HMS-I1 1μM R01 exp46]]|-3.45| |[[:results:exp60|Vinblastine 0.002μM R01 exp60]]|-3.34| |[[:results:exp460|BML-284 0.09μM R08 exp460]]|-3.27| |[[:results:exp45|Docetaxel 0.002μM R01 exp45]]|-3.24| |[[:results:exp59|UMK57 1μM R01 exp59]]|-3.09| |[[:results:exp184|Ixabepilone 0.004 to 0.005μM on day4 R04 exp184]]|-2.77| |[[:results:exp103|Taxol 0.004μM R03 exp103]]|-2.63| |[[:results:exp190|Vincristine 0.0005μM R04 exp190]]|-2.34| |[[:results:exp310|2-Methoxyestradiol 0.55μM R07 exp310]]|-2.08| |[[:results:exp294|Nutlin-3A 1.6μM R06 exp294]]|-1.99| |[[:results:exp6|Bortezomib 0.005μM R00 exp6]]|-1.93| |[[:results:exp36|TRAIL 50ng/ml R00 exp36]]|-1.9| |[[:results:exp231|Epothilone-B 0.0015μM R05 exp231]]|-1.88| |[[:results:exp412|THZ531 0.11 to 0.125 to 0.35μM on day4 then day6 R07 exp412]]|-1.81| |[[:results:exp242|Radicicol 0.16μM R05 exp242]]|-1.8| |[[:results:exp27|Pimelic-diphenylamide-106 0.5μM R00 exp27]]|-1.73| |[[:results:exp66|BI-D1870 3.15μM R02 exp66]]|1.73| |[[:results:exp272|CHIR-124 0.04μM R06 exp272]]|1.89| |[[:results:exp97|BI-6727 0.0125μM R03 exp97]]|2.17| |[[:results:exp343|Centrinone 0.5μM R07 exp343]]|3.49| |[[:results:exp95|BI-2536 0.0042μM R03 exp95]]|3.65| |[[:results:exp17|DABN 20μM R00 exp17]]|5.07| |[[:results:exp256|HMS-I1 10μM R06 exp256]]|6.17| |[[:results:exp64|Nocodazole 0.2μM R02 exp64]]|6.63| |[[:results:exp93|DABN racemic mixture R03 exp93]]|7.09| |[[:results:exp244|SB743921 0.001μM R05 exp244]]|7.14| |[[:results:exp33|Rotenone 2μM R00 exp33]]|7.3| |[[:results:exp208|Vinblastine 0.015μM R05 exp208]]|7.56| |[[:results:exp24|Nocodazole 0.2μM R00 exp24]]|7.81| |[[:results:exp108|Vinblastine 0.2μM R03 exp108]]|7.82| |[[:results:exp94|Nocodazole 0.1μM R03 exp94]]|8.13| |[[:results:exp111|R-DABN 8μM R03 exp111]]|8.19| ^Gene^Correlation^ |[[:human genes:m:mad2l1bp|MAD2L1BP]]|0.858| |[[:human genes:k:kntc1|KNTC1]]|0.828| |[[:human genes:z:zw10|ZW10]]|0.789| |[[:human genes:z:zwilch|ZWILCH]]|0.762| |[[:human genes:m:mad1l1|MAD1L1]]|0.761| |[[:human genes:b:bub1b|BUB1B]]|0.752| |[[:human genes:m:mad2l1|MAD2L1]]|0.728| |[[:human genes:r:rbm14|RBM14]]|0.684| |[[:human genes:b:bub3|BUB3]]|0.678| |[[:human genes:c:cdc20|CDC20]]|0.573| |[[:human genes:f:fntb|FNTB]]|0.496| |[[:human genes:f:fnta|FNTA]]|0.494| |[[:human genes:c:cenpe|CENPE]]|0.437| |[[:human genes:c:ccnb1|CCNB1]]|0.432| Global Fraction of Cell Lines Where Essential: 16/739 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|0/1| |bile duct|0/28| |blood|1/28| |bone|0/26| |breast|0/33| |central nervous system|1/56| |cervix|1/4| |colorectal|0/17| |esophagus|0/13| |fibroblast|0/1| |gastric|0/16| |kidney|0/21| |liver|2/20| |lung|3/75| |lymphocyte|0/16| |ovary|0/26| |pancreas|0/24| |peripheral nervous system|0/16| |plasma cell|0/15| |prostate|0/1| |skin|0/24| |soft tissue|0/9| |thyroid|0/2| |upper aerodigestive|0/22| |urinary tract|3/29| |uterus|0/5| == Essentiality in NALM6 == * **Essentiality Rank**: 3692 * **Expression level (log2 read counts)**: 5.24 {{:chemogenomics:nalm6 dist.png?nolink |}}